menu ☰
menu ˟

FDA approves Imfinzi for unresectable stage III NSCLC tumors

16 Feb 2018
The FDA has approved durvalumab for treatment of patients with stage III non-small cell lung cancer with unresectable tumors and whose cancer has not progressed after treatment with chemoradiation, according to an FDA press announcement.The approval ...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.